Sustained pricing pressure in generics
Pricing pressure and competitive intensity continue to impact the US and API businesses, potentially limiting margin expansion.
APLLTD / Q4-FY26 / risks
Keep the risk register visible.
Alembic Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
US branded business margin drag
The launch of Pivya and the US branded specialty business will drag margins by 100-150 bps in the near term, with uncertain timing of breakeven.
R&D productivity and elevated spend
R&D spend increased to 11% of revenue in Q4, and guidance for FY27 is elevated at ₹750-800 crore; returns on this investment are uncertain.
New facility ramp-up delays
F2 and F3 facilities are still underutilized (40-60% on some lines), and revenue contribution from contract manufacturing may take time to materialize.